Acura Pharmaceuticals (STU:HD4B) ROA %: 10.63% (As of Dec. 2021)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals ROA %?

Acura Pharmaceuticals STU:HD4B 16 ROA % is 10.63% as of Dec. 2021. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Acura Pharmaceuticals's annualized Net Income for the quarter that ended in Dec. 2021 was €0.10 Mil. Acura Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2021 was €0.98 Mil. Therefore, Acura Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2021 was 10.63%.

The historical rank and industry rank for Acura Pharmaceuticals's ROA % or its related term are showing as below:

STU:HD4B's ROA % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.69
* Ranked among companies with meaningful ROA % only.

Acura Pharmaceuticals  (STU:HD4B) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=0.104/0.978
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.104 / 0.128)*(0.128 / 0.978)
=Net Margin %*Asset Turnover
=81.25 %*0.1309
=10.63 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Acura Pharmaceuticals ROA % Related Terms


Acura Pharmaceuticals ROA % Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals ROA % Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -82.27 -116.81 -161.84 -53.20 -71.12

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.57 -57.41 -80.63 -64.43 10.63

STU:HD4B vs VFRM, THCT, CBGL: ROA % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals ROA % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's ROA % falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals ROA % Calculation

Acura Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-0.778/( (1.427+0.761)/ 2 )
=-0.778/1.094
=-71.12 %

Acura Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2021 is calculated as:

ROA %=Net Income (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=0.104/( (1.195+0.761)/ 2 )
=0.104/0.978
=10.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2021) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of 10.63% mean?
Acura Pharmaceuticals (STU:HD4B) has a ROA % of 10.63% as of Dec. 2021. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' ROA % too high?
Acura Pharmaceuticals' current ROA % is 10.63%. The Drug Manufacturers industry median ROA % is 2.69. Acura Pharmaceuticals' value of 10.63% is 295.2% above this industry median. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' ROA % compare to VFRM and THCT?
Acura Pharmaceuticals' ROA % of 10.63% can be compared against companies in the Drug Manufacturers industry. The industry median ROA % is 2.69. Acura Pharmaceuticals' value of 10.63% is 295.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acura Pharmaceuticals's current ROA % of 10.63% is 295.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Acura Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acura Pharmaceuticals's current ROA % is 10.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current ROA % of 10.63%. The current ROA % is 10.63% and 295.2% above the Drug Manufacturers industry median of 2.69. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current ROA % is 10.63% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price